Description: Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company. The Company is focused on development and commercialization of diagnostic and therapeutic products based on radiopharmaceuticals, or molecularly-targeted radiation (MTR). MTR is a novel therapeutic approach that selectively delivers radiation to cells that exhibit certain molecular profiles or targets that may be indicative of cancer. The Company's MTR products such as TLX-250 diagnosis and treatment of renal (kidney), TLX-591 treatment of metastatic castrate-resistant prostate cancer, and TLX-101 treatment of glioblastoma (brain cancer).
Home Page: telixpharma.com
TLX Technical Analysis
55 Flemington Road
North Melbourne,
VIC
3051
Australia
Phone:
61 3 3093 3897
Officers
| Name | Title |
|---|---|
| Dr. Christian P. Behrenbruch BEng(Hons), DPhil(Oxon), GAICD, J.D., M.B.A., MBA | Co-Founder, Group MD, CEO & Exec. Director |
| Dr. Andreas Kluge M.D., Ph.D. | Chief Medical Advisor & Director |
| Mr. Darren Smith B.Bus., FCPA, M.B.A. | Group Chief Financial Officer |
| Dr. Michael Wheatcroft B.Sc., BSc(Hons), Ph.D., Ph.D., (Cantab) | Chief Scientist |
| Ms. Kyahn Williamson | Sr. VP of Corp. Communications & Investor Relations |
| Ms. Melanie Farris (AGIA, ACG, ACIS) BComn, B.Com., GradDip, M.A.I.C. | Sr. VP of Global Governance, Risk & Compliance |
| Ms. Lena Moran-Adams | Gen. Counsel |
| Ms. Amanda Griffin | Communications Mang. |
| Mr. Christian Davis | VP Sales and Marketing, EMEA |
| Ms. Meredith Crowe | Interim Sr. VP of Global People & Culture |
Exchange: AU
Country: AU : Australia
Currency: Australian Dollar (A$)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 21.0084 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 20.4052 |
| Price-to-Sales TTM: | 77.9352 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |